Published in J Am Coll Cardiol on August 24, 2010
Mesenchymal stem cells: biology, pathophysiology, translational findings, and therapeutic implications for cardiac disease. Circ Res (2011) 4.75
Cell therapy for heart failure: a comprehensive overview of experimental and clinical studies, current challenges, and future directions. Circ Res (2013) 3.56
Cardiac muscle regeneration: lessons from development. Genes Dev (2011) 1.86
The advancing field of cell-based therapy: insights and lessons from clinical trials. J Am Heart Assoc (2013) 1.40
Vascular endothelial growth factor in heart failure. Nat Rev Cardiol (2013) 1.16
Induced pluripotent stem cell intervention rescues ventricular wall motion disparity, achieving biological cardiac resynchronization post-infarction. J Physiol (2013) 1.08
Pharmacologic and genetic strategies to enhance cell therapy for cardiac regeneration. J Mol Cell Cardiol (2011) 1.04
Bone marrow-derived human mesenchymal stem cells express cardiomyogenic proteins but do not exhibit functional cardiomyogenic differentiation potential. Stem Cells Dev (2012) 1.02
Energy metabolism plasticity enables stemness programs. Ann N Y Acad Sci (2012) 1.02
Cardiac stem cell therapy for cardiac repair. Curr Treat Options Cardiovasc Med (2014) 0.96
Endometrial regenerative cells for treatment of heart failure: a new stem cell enters the clinic. J Transl Med (2013) 0.96
Extracellular matrix remodeling following myocardial infarction influences the therapeutic potential of mesenchymal stem cells. Stem Cell Res Ther (2014) 0.96
A novel suture-based method for efficient transplantation of stem cells. J Biomed Mater Res A (2012) 0.94
Preconditioning of bone marrow mesenchymal stem cells by prolyl hydroxylase inhibition enhances cell survival and angiogenesis in vitro and after transplantation into the ischemic heart of rats. Stem Cell Res Ther (2014) 0.94
Pre-conditioned mesenchymal stem cells: a better way for cell-based therapy. Stem Cell Res Ther (2013) 0.93
Stem cell therapy for heart failure: Ensuring regenerative proficiency. Trends Cardiovasc Med (2016) 0.93
Position Paper of the European Society of Cardiology Working Group Cellular Biology of the Heart: cell-based therapies for myocardial repair and regeneration in ischemic heart disease and heart failure. Eur Heart J (2016) 0.91
The survey on cellular and engineered tissue therapies in Europe in 2011. Tissue Eng Part A (2013) 0.91
Multipotent (adult) and pluripotent stem cells for heart regeneration: what are the pros and cons? Stem Cell Res Ther (2013) 0.90
Preconditioning of mesenchymal stem cells for improved transplantation efficacy in recessive dystrophic epidermolysis bullosa. Stem Cell Res Ther (2014) 0.89
Human endometrial stem cells confer enhanced myocardial salvage and regeneration by paracrine mechanisms. J Cell Mol Med (2013) 0.87
Tongxinluo promotes mesenchymal stem cell tube formation in vitro. J Zhejiang Univ Sci B (2011) 0.87
Optimized delivery system achieves enhanced endomyocardial stem cell retention. Circ Cardiovasc Interv (2013) 0.86
Bone marrow cell injection for chronic myocardial ischemia: the past and the future. J Cardiovasc Transl Res (2011) 0.85
Primed 3D injectable microniches enabling low-dosage cell therapy for critical limb ischemia. Proc Natl Acad Sci U S A (2014) 0.85
Induction of cardiac myogenic lineage development differs between mesenchymal and satellite cells and is accelerated by bone morphogenetic protein-4. J Mol Cell Cardiol (2012) 0.83
A comparison of the efficacy of transplantation of bone marrow-derived mesenchymal stem cells and unrestricted somatic stem cells on outcome after acute myocardial infarction. Stem Cell Res Ther (2012) 0.83
Postinfarction Functional Recovery Driven by a Three-Dimensional Engineered Fibrin Patch Composed of Human Umbilical Cord Blood-Derived Mesenchymal Stem Cells. Stem Cells Transl Med (2015) 0.83
Mechanical dyssynchrony precedes QRS widening in ATP-sensitive K⁺ channel-deficient dilated cardiomyopathy. J Am Heart Assoc (2013) 0.82
Circulating very small embryonic-like stem cells in cardiovascular disease. J Cardiovasc Transl Res (2010) 0.82
Regenerative medicine: on the vanguard of health care. Mayo Clin Proc (2011) 0.81
Inhibition of DNA topoisomerase II selectively reduces the threat of tumorigenicity following induced pluripotent stem cell-based myocardial therapy. Stem Cells Dev (2014) 0.81
Concomitant Retrograde Coronary Venous Infusion of Basic Fibroblast Growth Factor Enhances Engraftment and Differentiation of Bone Marrow Mesenchymal Stem Cells for Cardiac Repair after Myocardial Infarction. Theranostics (2015) 0.80
Congestive Heart Failure Cardiopoietic Regenerative Therapy (CHART-1) trial design. Eur J Heart Fail (2015) 0.80
Intramyocardial transplantation and tracking of human mesenchymal stem cells in a novel intra-uterine pre-immune fetal sheep myocardial infarction model: a proof of concept study. PLoS One (2013) 0.79
Cardiac stem cell therapies inch toward clinical litmus test. Nat Biotechnol (2013) 0.79
Discrepant Results of Experimental Human Mesenchymal Stromal Cell Therapy after Myocardial Infarction: Are Animal Models Robust Enough? PLoS One (2016) 0.79
Stem cells for cardiac repair: an introduction. J Geriatr Cardiol (2013) 0.79
Mesenchymal stem cells in cardiac regeneration: a detailed progress report of the last 6 years (2010-2015). Stem Cell Res Ther (2016) 0.79
Effect of fatty acids on human bone marrow mesenchymal stem cell energy metabolism and survival. PLoS One (2015) 0.78
Cardiopoietic cell therapy for advanced ischemic heart failure: results at 39 weeks of the prospective, randomized, double blind, sham-controlled CHART-1 clinical trial. Eur Heart J (2016) 0.78
Regenerative Therapy Prevents Heart Failure Progression in Dyssynchronous Nonischemic Narrow QRS Cardiomyopathy. J Am Heart Assoc (2015) 0.77
Regenerative principles enrich cardiac rehabilitation practice. Am J Phys Med Rehabil (2014) 0.77
"Second-generation" stem cells for cardiac repair. World J Stem Cells (2015) 0.77
New strategies for improving stem cell therapy in ischemic heart disease. Heart Fail Rev (2016) 0.77
Cardiac Repair and Regeneration: The Value of Cell Therapies. Eur Cardiol (2015) 0.76
Boot camp for mesenchymal stem cells. J Am Coll Cardiol (2010) 0.76
The Epigenetic Regulator HDAC1 Modulates Transcription of a Core Cardiogenic Program in Human Cardiac Mesenchymal Stromal Cells Through a p53-Dependent Mechanism. Stem Cells (2016) 0.75
Treatment with platelet lysate induces endothelial differentation of bone marrow mesenchymal stem cells under fluid shear stress. EXCLI J (2014) 0.75
Long noncoding RNA Braveheart promotes cardiogenic differentiation of mesenchymal stem cells in vitro. Stem Cell Res Ther (2017) 0.75
Cellular Therapy for Heart Failure. Curr Cardiol Rev (2016) 0.75
Differentiation of Bone Marrow Mesenchymal Stem Cells to Cardiomyocyte-Like Cells Is Regulated by the Combined Low Dose Treatment of Transforming Growth Factor-β1 and 5-Azacytidine. Stem Cells Int (2015) 0.75
Differentiation of Rat bone marrow Mesenchymal stem cells into Adipocytes and Cardiomyocytes after treatment with platelet lysate. Int J Hematol Oncol Stem Cell Res (2016) 0.75
Functional Effects of Delivering Human Mesenchymal Stem Cell-Seeded Biological Sutures to an Infarcted Heart. Biores Open Access (2016) 0.75
Transplantation of Epigenetically Modified Adult Cardiac c-Kit+ Cells Retards Remodeling and Improves Cardiac Function in Ischemic Heart Failure Model. Stem Cells Transl Med (2015) 0.75
The time window for therapy with peptide nanofibers combined with autologous bone marrow cells in pigs after acute myocardial infarction. PLoS One (2015) 0.75
Integrate and boost: bioscaffolds nurture the cardiac regenerative paradigm. Stem Cell Res Ther (2015) 0.75
Transcription factor-induced activation of cardiac gene expression in human c-kit+ cardiac progenitor cells. PLoS One (2017) 0.75
Generation and Assessment of Functional Biomaterial Scaffolds for Applications in Cardiovascular Tissue Engineering and Regenerative Medicine. Adv Healthc Mater (2015) 0.75
Cell Therapies in Cardiomyopathy: Current Status of Clinical Trials. Anal Cell Pathol (Amst) (2017) 0.75
Bone marrow cells regenerate infarcted myocardium. Nature (2001) 21.24
Pluripotency of mesenchymal stem cells derived from adult marrow. Nature (2002) 19.57
Adult cardiac stem cells are multipotent and support myocardial regeneration. Cell (2003) 18.09
Mesenchymal stem cells in health and disease. Nat Rev Immunol (2008) 11.14
Regenerative potential of cardiosphere-derived cells expanded from percutaneous endomyocardial biopsy specimens. Circulation (2007) 8.62
Isolation and expansion of adult cardiac stem cells from human and murine heart. Circ Res (2004) 8.41
A randomized, double-blind, placebo-controlled, dose-escalation study of intravenous adult human mesenchymal stem cells (prochymal) after acute myocardial infarction. J Am Coll Cardiol (2009) 8.13
Epicardial progenitors contribute to the cardiomyocyte lineage in the developing heart. Nature (2008) 7.03
Adult bone marrow-derived cells for cardiac repair: a systematic review and meta-analysis. Arch Intern Med (2007) 6.68
Differentiation of human embryonic stem cells to cardiomyocytes: role of coculture with visceral endoderm-like cells. Circulation (2003) 6.30
A murine model of Holt-Oram syndrome defines roles of the T-box transcription factor Tbx5 in cardiogenesis and disease. Cell (2001) 5.77
Stem-cell therapy for cardiac disease. Nature (2008) 5.75
Stem-cell-based therapy and lessons from the heart. Nature (2008) 4.54
Unchain my heart: the scientific foundations of cardiac repair. J Clin Invest (2005) 4.25
Allogeneic mesenchymal stem cells restore cardiac function in chronic ischemic cardiomyopathy via trilineage differentiating capacity. Proc Natl Acad Sci U S A (2009) 4.21
Human mesenchymal stem cells engraft and demonstrate site-specific differentiation after in utero transplantation in sheep. Nat Med (2000) 3.94
Sizing up the heart: development redux in disease. Genes Dev (2003) 3.52
Engraftment, differentiation, and functional benefits of autologous cardiosphere-derived cells in porcine ischemic cardiomyopathy. Circulation (2009) 3.45
Stem cell differentiation requires a paracrine pathway in the heart. FASEB J (2002) 2.55
MesP1 drives vertebrate cardiovascular differentiation through Dkk-1-mediated blockade of Wnt-signalling. Nat Cell Biol (2008) 2.55
Origins and fates of cardiovascular progenitor cells. Cell (2008) 2.55
Characterization of the optimal culture conditions for clinical scale production of human mesenchymal stem cells. Stem Cells (2005) 2.53
Cardiac cell therapy--mixed results from mixed cells. N Engl J Med (2006) 2.52
Aging and disease as modifiers of efficacy of cell therapy. Circ Res (2008) 2.51
Concise review: mesenchymal stromal cells: potential for cardiovascular repair. Stem Cells (2008) 2.39
Activation of cardiac progenitor cells reverses the failing heart senescent phenotype and prolongs lifespan. Circ Res (2008) 2.31
Homing and engraftment of progenitor cells: a prerequisite for cell therapy. J Mol Cell Cardiol (2008) 2.13
Multimodality noninvasive imaging demonstrates in vivo cardiac regeneration after mesenchymal stem cell therapy. J Am Coll Cardiol (2006) 2.10
Enhanced cardiogenesis in embryonic stem cells overexpressing the GATA-4 transcription factor. Development (1997) 2.07
Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med (2007) 1.97
Pre-treatment of mesenchymal stem cells with a combination of growth factors enhances gap junction formation, cytoprotective effect on cardiomyocytes, and therapeutic efficacy for myocardial infarction. J Am Coll Cardiol (2008) 1.86
Retinoic acid accelerates embryonic stem cell-derived cardiac differentiation and enhances development of ventricular cardiomyocytes. J Mol Cell Cardiol (1997) 1.60
Potential of stem-cell-based therapies for heart disease. Nature (2006) 1.56
The human adult cardiomyocyte phenotype. Cardiovasc Res (2003) 1.54
Hepatocyte growth factor or vascular endothelial growth factor gene transfer maximizes mesenchymal stem cell-based myocardial salvage after acute myocardial infarction. Circulation (2009) 1.54
Cardioinductive network guiding stem cell differentiation revealed by proteomic cartography of tumor necrosis factor alpha-primed endodermal secretome. Stem Cells (2007) 1.16
Genomic chart guiding embryonic stem cell cardiopoiesis. Genome Biol (2008) 1.13
Structural adaptation of the nuclear pore complex in stem cell-derived cardiomyocytes. Circ Res (2003) 1.11
Infrastructure development for human cell therapy translation. Clin Pharmacol Ther (2007) 1.10
Stem cell transplant into preimplantation embryo yields myocardial infarction-resistant adult phenotype. Stem Cells (2009) 1.01
Guided stem cell cardiopoiesis: discovery and translation. J Mol Cell Cardiol (2008) 1.00
The interleukin-6/interleukin-6-receptor system is activated in donor hearts. J Am Coll Cardiol (2002) 0.90
Bone-marrow-derived cells and heart repair. Curr Opin Organ Transplant (2008) 0.85
Cardiac progenitor cells from adult myocardium: homing, differentiation, and fusion after infarction. Proc Natl Acad Sci U S A (2003) 7.87
Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol (2013) 5.11
Somatic oxidative bioenergetics transitions into pluripotency-dependent glycolysis to facilitate nuclear reprogramming. Cell Metab (2011) 4.15
Efficacy and safety of apixaban compared with warfarin at different levels of predicted international normalized ratio control for stroke prevention in atrial fibrillation. Circulation (2013) 3.25
Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet (2007) 3.20
Kv1.5 channelopathy due to KCNA5 loss-of-function mutation causes human atrial fibrillation. Hum Mol Genet (2006) 3.15
Impact of intracoronary cell therapy on left ventricular function in the setting of acute myocardial infarction: a collaborative systematic review and meta-analysis of controlled clinical trials. J Am Coll Cardiol (2007) 3.05
Abnormal conduction and morphology in the atrioventricular node of mice with atrioventricular canal targeted deletion of Alk3/Bmpr1a receptor. Circulation (2007) 2.93
Repair of acute myocardial infarction by human stemness factors induced pluripotent stem cells. Circulation (2009) 2.93
ABCC9 mutations identified in human dilated cardiomyopathy disrupt catalytic KATP channel gating. Nat Genet (2004) 2.85
Opposing roles for p16Ink4a and p19Arf in senescence and ageing caused by BubR1 insufficiency. Nat Cell Biol (2008) 2.81
Phosphotransfer networks and cellular energetics. J Exp Biol (2003) 2.79
Myocardial gene expression in heart failure patients treated with cardiac resynchronization therapy responders versus nonresponders. J Am Coll Cardiol (2008) 2.68
Assessment of renal artery stenosis severity by pressure gradient measurements. J Am Coll Cardiol (2006) 2.61
Kir6.2 is required for adaptation to stress. Proc Natl Acad Sci U S A (2002) 2.60
Stem cell differentiation requires a paracrine pathway in the heart. FASEB J (2002) 2.55
Human endothelial progenitor cells tolerate oxidative stress due to intrinsically high expression of manganese superoxide dismutase. Arterioscler Thromb Vasc Biol (2004) 2.39
Metabolic plasticity in stem cell homeostasis and differentiation. Cell Stem Cell (2012) 2.36
Early aging-associated phenotypes in Bub3/Rae1 haploinsufficient mice. J Cell Biol (2006) 2.24
Mitochondrial oxidative metabolism is required for the cardiac differentiation of stem cells. Nat Clin Pract Cardiovasc Med (2007) 2.21
Frequency of abdominal aortic aneurysm in patients >60 years of age with coronary artery disease. Am J Cardiol (2005) 2.13
Fractional flow reserve and myocardial perfusion imaging in patients with angiographic multivessel coronary artery disease. JACC Cardiovasc Interv (2010) 2.08
Cardiac system bioenergetics: metabolic basis of the Frank-Starling law. J Physiol (2006) 2.06
Cardiac KATP channels in health and disease. J Mol Cell Cardiol (2005) 2.04
Improvement of left ventricular function after cardiac resynchronization therapy is predicted by tissue Doppler imaging echocardiography. Circulation (2004) 2.00
Heart failure with preserved ejection fraction in outpatients with unexplained dyspnea: a pressure-volume loop analysis. J Am Coll Cardiol (2010) 1.98
Cardiopoietic programming of embryonic stem cells for tumor-free heart repair. J Exp Med (2007) 1.97
Increased expression of BubR1 protects against aneuploidy and cancer and extends healthy lifespan. Nat Cell Biol (2012) 1.94
Predictors of improvement of unrepaired moderate ischemic mitral regurgitation in patients undergoing elective isolated coronary artery bypass graft surgery. Circulation (2009) 1.87
Percutaneous transvenous mitral annuloplasty: initial human experience with a novel coronary sinus implant device. Circ Cardiovasc Interv (2009) 1.77
iPS programmed without c-MYC yield proficient cardiogenesis for functional heart chimerism. Circ Res (2009) 1.77
Recommendations for successful training on methods of delivery of biologics for cardiac regeneration: a report of the International Society for Cardiovascular Translational Research. JACC Cardiovasc Interv (2010) 1.74
KATP channel knockout worsens myocardial calcium stress load in vivo and impairs recovery in stunned heart. Am J Physiol Heart Circ Physiol (2006) 1.74
Stable benefit of embryonic stem cell therapy in myocardial infarction. Am J Physiol Heart Circ Physiol (2004) 1.73
Coupling of cell energetics with membrane metabolic sensing. Integrative signaling through creatine kinase phosphotransfer disrupted by M-CK gene knock-out. J Biol Chem (2002) 1.72
Induced pluripotent stem cells: developmental biology to regenerative medicine. Nat Rev Cardiol (2010) 1.71
Tailored echocardiographic interventricular delay programming further optimizes left ventricular performance after cardiac resynchronization therapy. Heart Rhythm (2005) 1.70
Protection conferred by myocardial ATP-sensitive K+ channels in pressure overload-induced congestive heart failure revealed in KCNJ11 Kir6.2-null mutant. J Physiol (2006) 1.70
Adenylate kinase and AMP signaling networks: metabolic monitoring, signal communication and body energy sensing. Int J Mol Sci (2009) 1.67
Interference of drug-eluting stents with endothelium-dependent coronary vasomotion: evidence for device-specific responses. Circ Cardiovasc Interv (2008) 1.66
On the inappropriateness of noninvasive multidetector computed tomography coronary angiography to trigger coronary revascularization: a comparison with invasive angiography. JACC Cardiovasc Interv (2009) 1.66
CXCR4+/FLK-1+ biomarkers select a cardiopoietic lineage from embryonic stem cells. Stem Cells (2008) 1.63
Cardiac cell repair therapy: a clinical perspective. Mayo Clin Proc (2009) 1.62
Final results of a phase IIa, randomised, open-label trial to evaluate the percutaneous intramyocardial transplantation of autologous skeletal myoblasts in congestive heart failure patients: the SEISMIC trial. EuroIntervention (2011) 1.58
Early and late effects of cardiac resynchronization therapy on force-frequency relation and contractility regulating gene expression in heart failure patients. Heart Rhythm (2007) 1.57
KATP channel mutation confers risk for vein of Marshall adrenergic atrial fibrillation. Nat Clin Pract Cardiovasc Med (2007) 1.56
Knockout of Kir6.2 negates ischemic preconditioning-induced protection of myocardial energetics. Am J Physiol Heart Circ Physiol (2003) 1.56
Ranolazine decreases mechanosensitivity of the voltage-gated sodium ion channel Na(v)1.5: a novel mechanism of drug action. Circulation (2012) 1.56
KCNJ11 gene knockout of the Kir6.2 KATP channel causes maladaptive remodeling and heart failure in hypertension. Hum Mol Genet (2006) 1.53
ATP-sensitive K+ channel knockout compromises the metabolic benefit of exercise training, resulting in cardiac deficits. Diabetes (2004) 1.53
Unbiased plasma proteomics for novel diagnostic biomarkers in cardiovascular disease: identification of quiescin Q6 as a candidate biomarker of acutely decompensated heart failure. Eur Heart J (2012) 1.48
Effects of intravenous dobutamine on coronary vasomotion in humans. J Am Coll Cardiol (2003) 1.47
Comparison of 600 versus 300-mg Clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary coronary angioplasty. Am J Cardiol (2010) 1.46
Mitochondrial tolerance to stress impaired in failing heart. J Mol Cell Cardiol (2003) 1.45
Thrombus aspiration in primary percutaneous coronary intervention in high-risk patients with ST-elevation myocardial infarction: a real-world registry. Catheter Cardiovasc Interv (2010) 1.44
Cellular remodeling in heart failure disrupts K(ATP) channel-dependent stress tolerance. EMBO J (2003) 1.40
Myocardial positive pre-ejection velocity accurately detects presence of viable myocardium, predicts recovery of left ventricular function and bears a prognostic value after surgical revascularization. Eur Heart J (2007) 1.40
Energetic communication between mitochondria and nucleus directed by catalyzed phosphotransfer. Proc Natl Acad Sci U S A (2002) 1.40
Intracoronary and intravenous adenosine 5'-triphosphate, adenosine, papaverine, and contrast medium to assess fractional flow reserve in humans. Circulation (2003) 1.40
Magnetocardiography study on ventricular depolarization-current pattern in patients with brugada syndrome and complete right-bundle branch blocks. Pacing Clin Electrophysiol (2006) 1.39
Embryonic stem cell therapy of heart failure in genetic cardiomyopathy. Stem Cells (2008) 1.39
Synergistic effect of thrombus aspiration and abciximab in primary percutaneous coronary intervention. Catheter Cardiovasc Interv (2013) 1.39
Meta-Analysis of Cell-based CaRdiac stUdiEs (ACCRUE) in patients with acute myocardial infarction based on individual patient data. Circ Res (2015) 1.39
Visualization of three-dimensional cardiac electrical excitation using standard heart model and anterior and posterior magnetocardiogram. Int J Cardiovasc Imaging (2006) 1.38
ATP-sensitive K+ channel channel/enzyme multimer: metabolic gating in the heart. J Mol Cell Cardiol (2005) 1.38
Glycolytic network restructuring integral to the energetics of embryonic stem cell cardiac differentiation. J Mol Cell Cardiol (2010) 1.37
Atrioventricular valve development during late embryonic and postnatal stages involves condensation and extracellular matrix remodeling. Dev Biol (2006) 1.35
Platelet lysate consisting of a natural repair proteome supports human mesenchymal stem cell proliferation and chromosomal stability. Cell Transplant (2010) 1.34
Potassium channel openers protect cardiac mitochondria by attenuating oxidant stress at reoxygenation. Am J Physiol Heart Circ Physiol (2002) 1.32
Role of imaging in cardiac stem cell therapy. J Am Coll Cardiol (2007) 1.32
Sarcolemmal ATP-sensitive K(+) channels control energy expenditure determining body weight. Cell Metab (2010) 1.31
Clinical and translational science: from bench-bedside to global village. Clin Transl Sci (2010) 1.30
Tandem function of nucleotide binding domains confers competence to sulfonylurea receptor in gating ATP-sensitive K+ channels. J Biol Chem (2002) 1.29
Gene knockout of the KCNJ8-encoded Kir6.1 K(ATP) channel imparts fatal susceptibility to endotoxemia. FASEB J (2006) 1.28
Program of cell survival underlying human and experimental hibernating myocardium. Circ Res (2004) 1.27